Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

ICAO Headhunter placed an additional share issue to exchange HeadHunter shares

2/1/24 HEAD

UWC has changed its CEO again

2/1/24 UWGN

Board of Directors of Rosgosstrakh recommended that dividends be paid for 2022

1/31/24 RGSS

RusHydro summarized the results of its work in 2023

1/31/24 HYDR

Polymetal will talk about projects in Tajikistan

1/31/24 POLY

M.Video-Eldorado will open at least 100 new stores in 2024

1/31/24 MVID

Moscow Exchange will start trading in shares of United Medical Group tomorrow

1/31/24 GEMC

Astra shipments up 75% in 2023

1/31/24 ASTR

MD Medical shareholders to discuss redomiciliation to Russia

1/31/24 MDMG

Revenue of YES! discounters increased by 19.8%

1/31/24 OKEY